Dyne Therapeutics (DYN) News Today $26.16 +0.06 (+0.23%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Franklin Resources Inc. Cuts Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)Franklin Resources Inc. decreased its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 21.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,342,500 shares of the company's stock aDecember 18 at 4:54 AM | marketbeat.comRobert W. Baird Initiates Coverage on Dyne Therapeutics (NASDAQ:DYN)December 16 at 1:53 AM | americanbankingnews.comState Street Corp Raises Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)State Street Corp increased its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 13.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,641,859 shares of the compaDecember 15 at 3:52 AM | marketbeat.comDyne Therapeutics initiated with an Outperform at BairdDecember 14, 2024 | markets.businessinsider.comDyne Therapeutics (NASDAQ:DYN) Upgraded to "Strong-Buy" at Raymond JamesRaymond James upgraded shares of Dyne Therapeutics to a "strong-buy" rating in a research report on Thursday.December 14, 2024 | marketbeat.comBaird Initiates Coverage of Dyne Therapeutics (DYN) with Outperform RecommendationDecember 13, 2024 | msn.comDyne Therapeutics initiated with Outperform at BairdDecember 13, 2024 | msn.comDyne Therapeutics (NASDAQ:DYN) Shares Gap Up - Here's What HappenedDyne Therapeutics (NASDAQ:DYN) Shares Gap Up - Should You Buy?December 13, 2024 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Now Covered by Robert W. BairdRobert W. Baird started coverage on shares of Dyne Therapeutics in a research report on Friday. They set an "outperform" rating and a $46.00 price objective for the company.December 13, 2024 | marketbeat.com29,694 Shares in Dyne Therapeutics, Inc. (NASDAQ:DYN) Purchased by Y Intercept Hong Kong LtdY Intercept Hong Kong Ltd acquired a new stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 29,694 shares of the company's stock, valued aDecember 13, 2024 | marketbeat.comInsider Selling: Dyne Therapeutics, Inc. (NASDAQ:DYN) SVP Sells 1,455 Shares of StockDecember 12, 2024 | insidertrades.comPoint72 Asset Management L.P. Sells 255,038 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)Point72 Asset Management L.P. reduced its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 71.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 102,480 shares of the company's stock afterDecember 9, 2024 | marketbeat.comThe Manufacturers Life Insurance Company Has $3.82 Million Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)The Manufacturers Life Insurance Company trimmed its position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 15.9% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 106,215 shares of the company's stock after selling 20,029 shares during the peDecember 8, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Has $23.30 Million Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)Charles Schwab Investment Management Inc. boosted its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 7.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 648,652 shares of the company's stockDecember 6, 2024 | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Shares Acquired by RA Capital Management L.P.RA Capital Management L.P. raised its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 5.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,381,144 shares of the company's stock after aDecember 5, 2024 | marketbeat.comRTW Investments LP Has $244.93 Million Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)RTW Investments LP boosted its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 6.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 6,818,641 shares of the company's stock after buying an additional 431,503 shares during theDecember 5, 2024 | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Recommendation of "Buy" from AnalystsDyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) has received a consensus recommendation of "Buy" from the eleven analysts that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, nine have assigned a buy recommendation and oneDecember 5, 2024 | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Shares Purchased by Janus Henderson Group PLCJanus Henderson Group PLC raised its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 47.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,813,163 shares of the company's stock aftDecember 4, 2024 | marketbeat.com65,482 Shares in Dyne Therapeutics, Inc. (NASDAQ:DYN) Bought by HighVista Strategies LLCHighVista Strategies LLC acquired a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 65,482 shares of the company's stock, valued at approximatelyDecember 3, 2024 | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Position Lessened by Holocene Advisors LPHolocene Advisors LP trimmed its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 4.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,982,640 shares of the coDecember 3, 2024 | marketbeat.comFmr LLC Has $324.24 Million Stake in Dyne Therapeutics, Inc. (NASDAQ:DYN)Fmr LLC grew its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 69.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 9,026,697 shares of the company's stock after acquiring an addiDecember 1, 2024 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Trading Down 4.2% - Time to Sell?Dyne Therapeutics (NASDAQ:DYN) Stock Price Down 4.2% - Here's What HappenedNovember 29, 2024 | marketbeat.comEventide Asset Management LLC Sells 152,723 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)Eventide Asset Management LLC reduced its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 31.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 332,277 shares of the company's stockNovember 29, 2024 | marketbeat.comIntech Investment Management LLC Takes $927,000 Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)Intech Investment Management LLC purchased a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund purchased 25,814 shares of the company's stock, valued at approximately $927,000. Several other hedge fundsNovember 29, 2024 | marketbeat.comAcuta Capital Partners LLC Has $1.66 Million Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)Acuta Capital Partners LLC lowered its position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 78.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 46,200 shares of the company's stock after selling 166,300 sharesNovember 28, 2024 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Makes New Investment in Dyne Therapeutics, Inc. (NASDAQ:DYN)Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 41,157 shares of tNovember 27, 2024 | marketbeat.comDyne Therapeutics initiated with an Outperform at RBC CapitalNovember 27, 2024 | markets.businessinsider.comRBC Capital Initiates Coverage of Dyne Therapeutics (DYN) with Outperform RecommendationNovember 26, 2024 | msn.comDyne Therapeutics (NASDAQ:DYN) Now Covered by Analysts at Royal Bank of CanadaRoyal Bank of Canada initiated coverage on shares of Dyne Therapeutics in a research note on Tuesday. They set an "outperform" rating and a $45.00 price target on the stock.November 26, 2024 | marketbeat.com12 NASDAQ Stocks with Biggest Upside Potential According to AnalystsNovember 22, 2024 | insidermonkey.comDyne Therapeutics Inc. (DYN): Among the NASDAQ Stocks with Biggest Upside Potential According to AnalystsNovember 22, 2024 | msn.comJennison Associates LLC Raises Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)Jennison Associates LLC lifted its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 1.5% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,346,952 shares of the company's stock after purchasing an additional 19,730November 22, 2024 | marketbeat.comParagon Therapeutics Appoints Susanna High as Chief Executive OfficerNovember 21, 2024 | finance.yahoo.comJason P. Rhodes Sells 782 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) StockNovember 19, 2024 | insidertrades.com44,197 Shares in Dyne Therapeutics, Inc. (NASDAQ:DYN) Bought by State of New Jersey Common Pension Fund DState of New Jersey Common Pension Fund D acquired a new stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 44,197 shares of the company's stock, valued at approximately $1,588,000. SeNovember 19, 2024 | marketbeat.comChardan Capital Expects Lower Earnings for Dyne TherapeuticsDyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) - Research analysts at Chardan Capital decreased their FY2024 earnings estimates for Dyne Therapeutics in a note issued to investors on Wednesday, November 13th. Chardan Capital analyst K. Nakae now forecasts that the company will post earnings oNovember 18, 2024 | marketbeat.comHC Wainwright Predicts Weaker Earnings for Dyne TherapeuticsDyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) - Equities research analysts at HC Wainwright lowered their FY2024 earnings per share estimates for Dyne Therapeutics in a research note issued to investors on Wednesday, November 13th. HC Wainwright analyst A. Fein now forecasts that the companyNovember 18, 2024 | marketbeat.comShort Interest in Dyne Therapeutics, Inc. (NASDAQ:DYN) Increases By 9.1%Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) saw a significant increase in short interest in October. As of October 31st, there was short interest totalling 9,940,000 shares, an increase of 9.1% from the October 15th total of 9,110,000 shares. Based on an average trading volume of 1,230,000 shares, the short-interest ratio is presently 8.1 days.November 17, 2024 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Trading Down 7.1% - Time to Sell?Dyne Therapeutics (NASDAQ:DYN) Trading Down 7.1% - Should You Sell?November 15, 2024 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Shares Gap Down - Here's What HappenedDyne Therapeutics (NASDAQ:DYN) Shares Gap Down - Here's What HappenedNovember 14, 2024 | marketbeat.comDyne Therapeutics Reveals Q3 Results and Trial UpdatesNovember 14, 2024 | markets.businessinsider.comDyne Therapeutics Receives Buy Rating Following IND Clearance and Promising Trial UpdatesNovember 13, 2024 | markets.businessinsider.comPromising Developments at Dyne Therapeutics: Analyst Recommends ‘Buy’ Based on DYNE-101 and ‘251 Program ProgressNovember 13, 2024 | markets.businessinsider.comHC Wainwright Reiterates Buy Rating for Dyne Therapeutics (NASDAQ:DYN)HC Wainwright reaffirmed a "buy" rating and set a $55.00 target price on shares of Dyne Therapeutics in a research note on Wednesday.November 13, 2024 | marketbeat.comDyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 12, 2024 | markets.businessinsider.comLisanti Capital Growth LLC Has $622,000 Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)Lisanti Capital Growth LLC lowered its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 83.7% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 17,310 shares of the coNovember 12, 2024 | marketbeat.comDyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle DiseasesNovember 11, 2024 | seekingalpha.comDyne Therapeutics, Inc. (NASDAQ:DYN) Receives Consensus Rating of "Buy" from BrokeragesShares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) have earned a consensus rating of "Buy" from the ten research firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one hasNovember 10, 2024 | marketbeat.comDyne Therapeutics to Present at Upcoming Investor ConferencesNovember 7, 2024 | globenewswire.comDyne Therapeutics (NASDAQ:DYN) Shares Gap Down - Should You Sell?Dyne Therapeutics (NASDAQ:DYN) Shares Gap Down - Here's WhyNovember 4, 2024 | marketbeat.com Get Dyne Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter. Email Address Forbes rich list released… #1 to be assassinated? (Ad)Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies. To get the full details on the fake “energy crisis” of America, watch this now DYN Media Mentions By Week DYN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DYN News Sentiment▼0.640.71▲Average Medical News Sentiment DYN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DYN Articles This Week▼147▲DYN Articles Average Week Get Dyne Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Qiagen News Today Intra-Cellular Therapies News Today Roivant Sciences News Today Ascendis Pharma A/S News Today Revolution Medicines News Today Lantheus News Today Legend Biotech News Today Nuvalent News Today Blueprint Medicines News Today Elanco Animal Health News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DYN) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyne Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyne Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
